Member Info for gtc1507

It’s nice to be disagreeing on the extent of how positive outcome we’re seeking will be rather than having some people without fact or evidence claiming the negative 😂

A valid opinion too! Let’s see how 2025 plays out!

Detail below. Believe they also have Clarendon fund managers, Viridian growth, octopus from previous Allenby capital notes and no TR1 to say they’ve reduced since although that’s off the top of my head. DYOR there’s info out there

https://www.fusionantibodies-ir.com/content/investors/shareholder-information

At 2 October 2024, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:

SHAREHOLDER NO. OF ORDINARY SHARES % OF ISSUED SHARE CAPITAL

Unicorn Asset Management Limited 6,397,290 6.71%

Amati AIM VCT plc 4,716,463 4.94%

Rathbone Investment Management Ltd 4,513,062 4.73%

Invest Northern Ireland 3,197,865 3.35%

If an offer comes it’ll unlock Pandora’s box. Hopefully we get some decent news and price rerating before that in the coming months which means that we are closer to fair value

I had asked them a while back about the risk of low priced takeover - they were keen to stress that being listed meant any offer would have to be public and that anyone who was seriously interested would know they have a good institutional investor base who would not entertain anything unreasonable. I think they arent in the business of giving away their valuable tech at a fraction of its worth and most investors would be with them. Before FMI 25p might have been interesting now it’s much much higher than that for me being reasonable especially with their tech validations coming through soon.

It’s amazing it means their r&d is substantially derisked, more affordable and can be more ambitious. Aka optimal will be at the market sooner! They can also draw on the 20 FMI scientists and 20PHD STUDENTS at zero cost it’s amazing! Plus the £1m they’re front loading and the capital equipment which will improve their margins on higher value sales it’s going to be a fantastic new year and I envisage EBitda Positive much sooner than we thought. I think that the broker notes next issued will have big forecast upgrades in.

Well wouldn’t that be lovely. I’d say NCI would buy a licence for a hefty fee if it’s good, given they’re in the market of public good not sure they would want the exclusivity element of it so a hefty licence rather than a buyout? another pharma would tho snaffle them up. Any different opinions ?

I think we should definitely be there! Assuming their recovery continues and we get the results we think we’re going to from their validation. 50m MCAP is not demanding and the company has been at that valuation before without the tech and margins it now how

HAPPY NEW YEAR 🥳😜

Would be great wouldn’t it! Ambitoous thinking dark Ryder are you going to be the last trade of 2024 🥳😜

CEO said recent grant funding will have a transformational impact.

This was issued out after their sharesoc webinar:

“4. How will the recent grant funding benefit the company and will it help the company win larger contracts and accelerate growth? Will the grant cover you for just new internal projects, or will it extend to existing work including work with clients?

The grant funding allows us to do more R&D at a lower cost. The capital equipment element is provided free to Fusion and so reduces our cost of sales for relevant projects enhancing margins and making us more competitive. This includes some of the higher value projects. So, yes it will help the company to win larger contracts and accelerate growth.“

Shard were forecasting margins to be 39% by end if year and 61% next. Wonder how quickly this impact will be felt and these upgraded

I hope you’re right 🥳

Regardless it’s a #fab opportunity at this price IMO

I agree - doesn’t contemplate the scale of the opportunity right. I think we should see 15p easily by end of q4 Fy25

Https://x.com/share_talk/status/1873684367085854881?s=46

“Fusion Antibodies (FAB): 7p Target 15p

After some three years with its shares in the doghouse, made worse by the post pandemic hangover for biotechs, we have seen the FAB phoenix rise from the ashes. The driver in the recent past has been the prospect of what the stock market is very keen on, non-dilutive funding. In this instance, there is the prospect of approximately £1 million of direct funding for research & development initiatives, and access to up to £5 million of capital equipment. All of this coupled by the way that at the interim stage as reported in November FAB revenue had more than doubled, means that fans of the company are looking at a situation where 2025 could be a pivotal year. Before all the good news this autumn as recently as a year ago the shares were trading at 9p, and therefore one would expect this to be easily beaten in Q1 2025.“

https://t.co/3L2hKqE5pn

“ Investment case. In our view, Fusion is clearly undervalued compared with its peers. When balanced with FairJourney and its recent €900m valuation, FAB’s current market capitalisation of £4.2m reflects neither the investment made nor the technology. We believe that the market has not yet accounted for the current recovery in sales and orderbook, or for the potential of the new proprietary platforms (OptiMAL®, OptiPhage™ and AI/ML-Ab™). This is just a matter of time, and the current interim results trading statement presents FAB with a much improved outlook and stronger bases. ”

“ Given that FAB gives evidence of a strong recovery and that sales margins are improving, we are confident that investors will start to recognise the value of its leading antibody discovery technologies. There is a clear mismatch between Fusion’s service with the new technology offering and the current market cap of £4.20m. We believe that the current, improved market conditions will create investor confidence in the Company, bringing shareholder value. Great efforts are being made to support the business in new, developing markets (especially diagnostics, veterinary medicine and research antibodies), and commercial initiatives are gaining traction. This is exemplified by the recent extended collaboration with the US NCI.”

You should take a look at the research notes published by Shard capital recently. They give great detail on the company and some really promising predictions about its future.

They published a really detailed one on 17th September last year and upgraded their forecasts in one on 19th November.

Both can be found for free here

https://shardcapital.com/capital-markets/corporate-broking/research-portal/

You’re highlighting a nice risk to have that the company is attractive and likely to be subject to takeover so fair dos. I would say Adrian does appear to have done a lot more than previous CEOs to make significant strides forwards in extremely challenging times. he’s made the company much leaner, diversified their client base to make much less vulnerable to single failures, taken them much closer to profitability than ever and also landed some majorly significant partnerships that will transform the future of this company.

There’s 25m shares in issue in a range of 40- 160 plus p! Anyone coming in on the initial raise may have averaged down but there will still be a very strong base. Anyone offering will know that and will IMO want to make an offer that is at least in the range of acceptable

I think highly unlikely that the board would recommend below 25p and that was my assessment before last months news. I’d say they would be higher now and that we’re not far away from a decent rerate